Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases, today announced that Jason Ehrlich, M.D., Ph.D., co-founder and CEO, will present at the 44^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 4:00 p.m. PT.

Dr. Ehrlich will provide an overview of the company’s pipeline, including OLN324, a higher potency, higher molar dose VEGF/Ang2 bispecific antibody being evaluated in a fully-recruited Phase 1b head-to-head clinical trial versus faricimab for patients with wet (neovascular) age-related macular degeneration (wAMD) or diabetic macular edema (DME). Ollin is also advancing OLN102, a first-in-class, TSHR/IGF-1R bispecific antibody with the potential for best-in-disease safety and efficacy for thyroid eye disease (TED) and the underlying autoimmune condition, Graves’ disease.

About Ollin Biosciences

Established in 2023, Ollin Biosciences^TM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251217962207/en/